Incyte Corporation (INCY)

51,18 -0,56 (-1,08 %) À la clôture : 04:00PM EDT

Incyte Corporation

1801 Augustine Cut-Off
Wilmington, DE 19803
United States
302 498 6700
https://www.incyte.com

Secteur(s): Healthcare
Secteur d’activité: Biotechnology
Employés à temps plein: 2 524

Dirigeants clés

Nom	Titre	Payer	Exercé	Année de naissance
Mr. Herve Hoppenot	CEO & Chairman	2,89M	S.O.	1960
Ms. Christiana Stamoulis MBA	Executive VP & CFO	1,16M	S.O.	1971
Dr. Barry P. Flannelly M.B.A., Pharm.D.	Executive VP & GM of North America	996,28k	545,65k	1958
Dr. Steven H. Stein M.D.	Executive VP & Chief Medical Officer	1,22M	S.O.	1967
Dr. Pablo J. Cagnoni M.D., Ph.D.	President and Head of Research & Development	S.O.	S.O.	1963
Mr. Thomas Tray	VP of Finance, Chief Accounting Officer & Controller	S.O.	S.O.	1978
Mr. Michael James Morrissey	Executive VP & Head of Global Technical Operations	S.O.	S.O.	1964
Sheila A. Denton	Executive VP, General Counsel & Corporate Secretary	S.O.	S.O.	1966
Ms. Pamela M. Murphy	Vice President of Investor Relations & Corporate Communications	S.O.	S.O.	1951
Ms. Paula J. Swain	Executive Vice President of Human Resources	611,92k	4,21M	1958

Les montants ont été établis en date du 31 décembre 2022 et les valeurs de compensation concernent le dernier exercice fiscal clos à cette date. Le terme « rémunération » désigne le salaire, les bonus, etc. Le terme « exercé » est utilisé pour la valeur des options exercées au cours de l’exercice fiscal. Devise exprimée en USD.

Description

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.

Gouvernance d’entreprise

L’ISS Governance QualityScore de Incyte Corporation en date du 1 avril 2024 est 8. Les scores principaux sont Audit : 3; Société : 6; Droits des actionnaires : 6; Compensation : 9.

Résultats de gouvernance d’entreprise offerts par Institutional Shareholder Services (ISS). Les résultats indiquent un rang décile par rapport à l’indice ou à la région. Un résultat décile de 1 indique un risque de gouvernance faible, tandis que 10 indique un risque de gouvernance élevé.